Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2021 Apr 12;15(4):e0009228. doi: 10.1371/journal.pntd.0009228

Crimean-Congo hemorrhagic fever virus antibody prevalence in Mauritanian livestock (cattle, goats, sheep and camels) is stratified by the animal’s age

Ansgar Schulz 1, Yahya Barry 2, Franziska Stoek 1, Aliou Ba 2, Jana Schulz 1, Mohamed L Haki 2, Miriam A Sas 1, Baba A Doumbia 3, Peter Kirkland 4, Mohamed Y Bah 3, Martin Eiden 1, Martin H Groschup 1,*
Editor: Andrea Marzi5
PMCID: PMC8081336  PMID: 33844691

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is one of the most widespread zoonotic arthropod-borne viruses in many parts of Africa, Europe and Asia. It belongs to the family of Nairoviridae in the genus of Orthonairovirus. The main reservoir and vector are ticks of the genus Hyalomma. Livestock animals (such as cattle, small ruminants and camels) develop a viremias lasting up to two weeks with absence of clinical symptoms, followed by seroconversion. This study was carried out to assess risk factors that affect seroprevalence rates in different species. In total, 928 livestock animal samples (cattle = 201; sheep = 247; goats = 233; camels = 247) from 11 out of 13 regions in Mauritania were assayed for CCHFV-specific immunoglobulin G (IgG) antibodies using enzyme-linked immunosorbent assays (ELISA) (including a novel indirect camel-IgG-specific CCHFV ELISA). Inconclusive results were resolved by an immunofluorescence assay (IFA). A generalized linear mixed-effects model (GLMM) was used to draw conclusions about the impact of certain factors (age, species, sex and region) which might have influenced the CCHFV antibody status of surveyed animals. In goats and sheep, about 15% of the animals were seropositive, whereas in cattle (69%) and camels (81%), the prevalence rate was significantly higher. On average, cattle and camels were up to twice to four times older than small ruminants. Interestingly, the seroprevalence in all species was directly linked to the age of the animals, i.e. older animals had significantly higher seroprevalence rates than younger animals. The highest CCHFV seroprevalence in Mauritania was found in camels and cattle, followed by small ruminants. The large proportion of positive animals in cattle and camels might be explained by the high ages of the animals. Future CCHFV prevalence studies should at least consider the age of surveyed animals in order to avoid misinterpretations.

Author summary

Crimean-Congo hemorrhagic fever virus (CCHFV) is a silent threat that repeatedly causes severe hemorrhagic disease in humans who have been in close contact with livestock of endemic countries. The detection of CCHFV IgG antibodies in livestock can be a first indication whether the virus circulates in a given region and is thus a valuable diagnostic tool for determining the endemic status. Interestingly, earlier data from Mauritania showed a noticeable difference in IgG prevalence between sheep (18%) and cattle (67%). In contrast to sheep and cattle, current monitoring data on CCHFV IgG antibody presence in camels and goats in Mauritania is very limited. This study was conducted to provide a comprehensive up-to-date overview of CCHFV seroprevalences in the four most important Mauritanian livestock species (cattle, sheep, goats and camels). It attempts to highlight the role of potential risk factors responsible for deviating prevalences. In addition, we developed a camel-specific IgG ELISA, which can be used in future CCHFV seroprevalence studies. Furthermore, findings of this study contribute to a better understanding of the current epidemiological CCHFV situation in sub-Saharan Africa and which role different livestock species play regarding the viral circulation in endemic regions.

Introduction

Crimean-Congo hemorrhagic fever virus (CCHFV) is one of the most widespread zoonotic arthropod-borne viruses distributed in many parts of Africa, Europe and Asia [1,2]. It belongs to the family of Nairoviridae in the genus of Orthonairovirus. Many livestock species like cattle, goats, sheep or camels can become infected with this virus and even develop viremia, but still do not showing clinical symptoms [3]. Humans can be infected by contact to infectious blood, tissue or other body fluids from viremic animals or patients. Nevertheless, most virus infections are caused by bites of infected Hyalomma ticks, which are the main reservoir and transmission vector of CCHFV [4]. In contrast to animals, infected people can suffer from severe symptoms, including hemorrhagic fever with case fatality rates ranging from 5% in Turkey [5] and up to 80% in China [6]. Livestock farming plays an important role for the income of the local population in Mauritania and represents an integral part of the Mauritanian economy [7]. The close contact between farmers and their animals, as well as insufficient medical or veterinary care in rural areas, bears a serious health risk for humans and animals. The first human case of CCHF in Mauritania was described in 1983 [8], triggering a first serological study for CCHFV antibodies in humans, cattle and rodents [9]. The first larger serological study was conducted by Gonzalez, LeGuenno [10] in sheep a prevalence of 18% was obtained. Another albeit much smaller study on sheep and goats in 2003 revealed a similar prevalence [11]. In 2013, in a first comprehensive study, cattle were tested solely for CCHFV IgG antibodies and a surprisingly high seropravalence of 67% was observed [12]. Investigations of cattle in Sudan [13] showed that collection site, age, husbandry system and tick infestation are the biggest risk factors for CCHFV seroprevalence. In addition, an age-related increase in CCHFV IgG antibody prevalence was already also observed in sheep [14] and cattle [13,15,16]. Therefore, this current study in Mauritania focused on potential risk factors (like age, species, sex and region) to reveal their impact on CCHFV seroprevalence rates in different livestock species. It provides a comprehensive overview of the current CCHFV IgG antibody circulation in Mauritania. We used already established tests for cattle, sheep and goats (in-house/adapted commercial assays) as well as a newly developed camel-IgG specific ELISA. Emphasis was particularly laid on previously understudied species in Mauritania (CCHFV infections in camels and goats).

Material and methods

Ethics statement

The samples were taken by ONARDEL (Office National de Recherche et de Développement de l’Elevage) in order to fulfill its governmental mandate to conduct livestock animal monitoring and surveillance programs for veterinary and zoonotic pathogens following all relevant national as well as international regulations and according to fundamental ethical principles.

Sampling sites and serum sample collection

Mauritania, located in West Africa south of the Western Sahara, has a size of 1,030,000 km2 and is one of the most sparsely populated countries in Africa due to the prevalent Saharan landscape. It is dominated by a very dry, hot and windy climate. Notable amounts of rainfall in terms of a rainy season occur only in the most southern border regions of the country, which extend to the Sahel. Livestock farming is mainly practiced in the form of nomadic pastoralism and semi-extensive husbandry. Solely stationary, irrigated agricultural practices/stable housing systems do not play a major role and are only rarely practiced. For this reason, breeding of cattle less adapted to drought and hot climate is mainly found in the south of the country, while small ruminants and camels are also kept in the northern regions [17,18]. The country itself is divided into 13 different regions, which are subdivided in 44 departments. In 2015, serum samples were taken from cattle (n = 201), sheep (n = 247), goats (n = 233) and camels (n = 247) from 11 out of 13 regions (Fig 1 and Table 1). Samples from the capital region Nouakchott originated from a large abattoir that is connected with one of the most important livestock markets in this region. Within the regions, one to a maximum of three different flocks from local farmers were sampled. Considering the relatively small size of the sampled flocks, we decided to consolidate the animals region-wise. The sampling region "Nouakchott" constitutes an exception, since the samples were taken in the most important slaughterhouse/livestock market. Livestock from all over the country were driven up to this market/slaughter house. Given the large size of the country and the lack of infrastructure especially in rural the areas, it was not feasible to take samples from all species in each region. Besides, political conflicts in the border regions and the partly limited compliance of livestock owners also impaired the sampling framework. Therefore, a “convenience sampling” was performed. For 873 of 928 samples, the age and sex of the sampled animals were available.

Fig 1. Map of Mauritania which shows the proportion and total number of each different animal species sampled in each region.

Fig 1

All sampled regions are highlighted in red. For more detailed information on prevalence and numbers, please refer to Table 1. The base layer of this modified map originated from Natural Earth (https://www.naturalearthdata.com/).

Table 1. Results of seroepidemiogical studies in cattle, goats, sheep and camels in Mauritania.

Region Cattle Goats Sheep Camels
p/n prev. (%) p/n prev. (%) p/n prev. (%) p/i/n prev. (%) inc. (%)
Adrar - - - - - - 5/0/5 100 0
(49–100) (0–52)
Assaba - - 8/28 29 7/32 21 - - -
(13–49) (9–40)
Brakna 14/28 50 2/8 25 5/10 50 - - -
(31–69) (3–65) (19–81)
Guidimaka - - 2/39 5 2/32 6 - - -
(1–17) (1–21)
Hodh Ech Chargui 39/41 95 15/41 37 6/40 15 - - -
(83–99) (22–53) (6–30)
Hodh El Gharbi 35/53 66 - - 17/81 21 - - -
(52–78) (13–31)
Nouakchott* 43/65 66 - - - - 83/3/93 89 3
(53–77) (81–91) (1–9)
Inchiri - - 8/51 16 2/29 7 6/5/21 29 24
(7–29) (1–23) (11–52) (8–47)
Tagant 7/14 50 0/55 0 0/5 0 - - -
(23–77) (0–6) (0–52)
Tiris Zemmour - - - - - - 7/1/8 88 13
(47–100) (0–53)
Trarza - - 0/11 0 0/18 0 98/13/120 82 11
(0–28) (0–19) (74–88) (6–18)
Total 138/201 69 (62–75) 35/233 15 (11–20) 39/247 16 (11–21) 199/22/247 81 (75–85) 9 (9–13)

p = positive    n = number of tested individuals    i = inconclusive result (ELISA)

* = Nouakchott, officially subdivided into three separated regions, has been treated as one region

95% confidence interval (CI %) in brackets

Establishment of a camel-specific in-house IgG CCHFV ELISA

A camel-specific CCHFV IgG ELISA was developed using His-tagged recombinant N-Protein of CCHFV-strain Kosovo Hoti (Accession no. DQ133507) as antigen. The same protein was used as the antigenic component in the other in-house assays for cattle, sheep and goats described in the section below. Half of the 96-Well F-Bottom microplates (Greiner Bio-One, Kremsmünster, Austria) were coated with 100 μl coating buffer (1x PBS; BSA 1%; pH 9) containing 0.2 μg of the antigen, whereas for the second half the antigen was omitted. The plates were incubated over night at 4°C and afterwards blocked for 1 h at 37°C with 200 μl blocking buffer (IDvet, Grabels, France). Serum samples were diluted 1:80 in serum dilution buffer (IDvet DB no. 11) and 50 μl of the dilution was applied twice each to the wells with antigen and the wells without antigen. The plates were then incubated for 1 h at 37°C and washed three times with 250 μl/well washing buffer (PBS-Tween 0.1%). The unlabeled goat- anti-lama IgG conjugate (Southern Biotech, Birmingham, USA) was diluted 1:1,500 in dilution buffer (IDvet DB no. 3), added (100 μl/well) and incubated for 1 h at 37°C. Afterwards plates were washed three times with 250 μl/well washing buffer (PBS-Tween 0.1%). To obtain a detectable signal, a rabbit anti-goat-HRP (Southern Biotech, Birmingham, USA) conjugate in ratio 1:3,000 (100 μl/well) was used and incubated for 1h at 37°C. Finally, the plate was washed again and 100 μl/well TMB solution (Bio-Rad, Hercules, USA) was added. After 10 min of incubation time the reaction was stopped with 100 μl 1M H2SO4 and measured with a Tecan plate reader Infinite 200 PRO (Tecan, Männedorf, Switzerland) at 450 nm against the reference wavelength of 620 nm. In order to exclude possible strong background reactions of the sera, which could falsify the result, a corrected OD (optical density) value was used (OD (av.) antigen-OD (av.) no antigen). The corrected OD value of the sample (R-sample) divided by the corrected OD value of the positive control (R-positive) gave the final result (fR) and was expressed as a percentage (fR = [R-sample/R-positive] * 100). The camel-specific in-house CCHFV IgG ELISA was validated using 42 camel sera from Australia as negative controls. According to the WHO (27 October 2019), Australia is officially free of CCHFV (https://www.who.int/emergencies/diseases/crimean-congo-haemorrhagicfever/Global_CCHFRisk_2017.jpg?ua=1). There were no field samples from Mauritanian camels available that could be considered as confirmed positive. Thus, to calculate a cut-off for the new camel-specific in-house IgG ELISA, the mean X and standard deviation SD of the corrected OD values of the negative controls were calculated and cut-off values were determined using the formula CutOff = aX+fSD, with a and f arbitrarily defined multipliers [19]. The repeatability of the test was evaluated using the Bland-Altman statistics [20,21]. To verify whether the ELISA is able to detect specific reactions in camelid sera against CCHFV IgG antibodies, an alpaca was immunized under laboratory conditions with the same recombinant N-Protein of CCHFV-strain Kosovo Hoti used for ELISA. Blood samples, including day 0, were collected after immunization and tested in the ELISA. The Kosovo-Hoti N-protein was expressed in an E. coli vector. In order to exclude an unspecific immune reaction of the alpaca against possible E. coli contamination, the samples were tested twice. In the first approach, the N-protein was coated as described before, in the second approach the plates were covered with an E. coli lysate (Table 2). Additionally, 12 serum samples from German zoo animals (Bactrian camel and dromedary) were used as negative controls to validate the newly developed ELISA.

Table 2. Immunization results (OD value and final result in % (fR = [R-sample/R-positive] * 100)) of the alpaca in the novel camel-specific IgG ELISA using two different coating proteins (N-Protein of Kosovi-Hoti and E. coli lysate).

Protein coated PC NC Alpaca
0 dpi 4 dpi 7 dpi 14 dpi 21 dpi 28 dpi
N-protein 1,568 -0,009 -0,006 0,044 -0,025 2,647 3,038 2,936
- -1% 0% 3% -2% 169% 194% 187%
E.coli lysate 0,047 0,101 0,106 0,136 0,082 0,095 0,090 0,033
- 6% 7% 9% 5% 6% 6% 2%

PC = positive control (camel field sample from Mauritania) dpi = days post immunization

NC = negative control (German zoo camel)

Serological investigation of cattle, sheep, goats and camels by in-house CCHFV IgG ELISA

All samples were tested according to a flow chart [22] combining different ELISA and IFA test systems. The sera from cattle, sheep and goats were assayed (twice in case of a positive result) with the respective species-specific in-house CCHFV IgG ELISA system [23,24]. Positive findings were tested during a second test run with adapted commercial ELISAs (Vector Best, Novosibirsk, Russia) to confirm the results. In case of divergent results, an adapted commercial IFA (Euroimmun, Lübeck, Germany) was used to obtain a final result. The diagnostic approach for the camel sera is described above.

Statistical analysis

The effects of age, species and sex on the CCHFV status were estimated using a generalized linear mixed-effects model (GLMM). The variables age, species and sex were considered as fixed effects. Including region as random regional effect with variance σregion2 led to the mixed model:

log(π1π)=β0+β1age+β2species+β3sex+bregion (1)

where π indicated the probability of an animal to be CCHFV positive. βi and b were the regression coefficients. Model reduction was performed as the variable sex did not show a significant effect. This led to the final model:

log(π1π)=β0+β1age+β2species+bregion (2)

Least-squares means were used for summarizing the effects of factors age and species. All analysis were performed in R (version 3.6.0 (2019-04-26)—"Planting of a Tree" [25] using the package lsmeans [26].

Results

Validation of the new camel-specific in-house IgG CCHFV ELISA

Forty-two Australian negative camel sera were used for the calculation and validation of the cut-off. Two cut-off values were calculated to define a range of inconclusive results. The upper cut-off value (a = 1, f = 2) was set to 19.96% and samples above this value were considered to be CCHFV positive. The lower cut-off value (a = 1, f = 1) was 10.45% and samples below this value were considered as negative. Samples showing OD values between these two cut-off values were considered to be inconclusive. Bland-Altman analysis [20] indicated good repeatability of the assay. However, two of the Australian sera showed a clear positive reaction in the ELISA. In the second test run, both were positive again, but deviated strongly from the first run. The rest of the samples showed no significant deviation in their values upon repetition. Since no positive reference field sera existed, a serum of an immunized alpaca was used as reference. On days 0, 4 and 7 post immunization, no specific reaction was detected by the ELISA. All sera collected after the 14th day post immunization were highly positive indicating that the ELISA is able to detect a specific seroconversion in camelids (Table 2) without any or only minimal reactivity to E. coli antigens itself. In addition, 12 camel sera originating from German zoos were tested negative (S1 Table).

Serological and statistical findings in cattle, goats, and sheep and camels

This study revealed considerable prevalence differences between animal species (Table 1 and Fig 2B). Cattle samples showed a seroprevalence of 68.66% with regional differences ranging from 50 to 95%. 16% of sheep (ranging from 0 to 50%) and 15% of goats (ranging from 0 to 37%) were positive. The prevalence of camels (81%), however, was even higher than in cattle. In total, thirty-two inconclusive sera from cattle (8/13), goats (1/13), and sheep (0/6) were additionally tested in the IFA, of which nine were finally considered positive.

Fig 2.

Fig 2

Effects of age (a) and species (b) regarding CCHFV IgG antibody status in different livestock species in Mauritania. Overall, for 850 of 928 samples, age, species, region and an unambiguous CCHFV-antibody status were available. All inconclusive results were excluded. Fig 2B summarizes the age dependency for all four species.

Moreover, we observed that older animals were more likely to be positive than younger animals (Table 3 and Fig 2A). A more detailed statistical analysis revealed a significant effect of age and species on the CCHFV status of the investigated animals, whereas sex had no influence. The region was another reason of random variability. Table 4 shows the comparison of the different age and species categories regarding their influence on the CCHFV antibody status. All other age categories were clearly different from group A (0–2 years). In addition, the second youngest age group B (3–4 years) differed almost from all others with one exception. There was no difference between B and the three next older cohorts C (5–6 years), D (7–10 years) and E (>10 years). When considering the species, there were no significant seroprevalence differences between goats and sheep nor between cattle and camels.

Table 3. Age-related prevalence of IgG-specific CCHFV antibodies in cattle, goats, sheep and camels.

Age group (years) Cattle (Øage: 5.84) Goats (Øage: 2.88) Sheep (Øage: 2.91) Camels (Øage: 11.55)
prev. (%) p/n prev. (%) p/n prev. (%) p/n prev. (%) p/n
A 0–2 37 22/60 8 8/95 8 9/116 25 2/8
(25–50) (4–16) (4–14) (3–65)
B 3–4 63 10/16 20 17/87 22 18/82 88 7/8
(35–85) (12–29) (14–32) (47–100)
C 5–6 92 23/25 20 4/20 28 12/43 100 5/5
(74–99) (6–44) (15–44) (48–100)
D 7–10 94 64/68 75 6/8 0(0–98) 0/1 90 9/10
(86–98) (35–97) (55–100)
E >10 85 17/20 - - - - 92 167/182
(62–97) (87–95)

prev. = prevalence    p = positive    n = number of tested individuals

95% confidence interval (CI %) in brackets

Table 4. Results of the generalized linear mixed-effects model (GLMM) for age (a) and species (b) after p-value adjustment using multivariate t-distribution.

The significance level was set to 0.05. Significant results were marked in bold.

a b
Differences between age groups p-value Differences between species p-value
A: 0–2 –B: 3–4 < 0.0001 Camel—Cattle 0.9609
A: 0–2 –C: 5–6 < 0.0001 Camel—Goat < 0.0001
A: 0–2 –D: 7–10 < 0.0001 Camel—Sheep < 0.0001
A: 0–2 –E: > 10 < 0.0001 Cattle—Goat < 0.0001
B: 3–4 –C: 5–6 0.5970 Cattle—Sheep < 0.0001
B: 3–4 –D: 7–10 0.0003 Goat—Sheep 0.9915
B: 3–4 –E: >10 0.0458
C: 5–6 –D: 7–10 0.0112
C: 5–6 –E: >10 0.3709
D: 7–10 –E: >10 0.7875

Discussion

The aim of the study was to reveal factors, which have a decisive impact on the CCHFV seroprevalences in different livestock species. For this purpose, several established diagnostic assays for serological IgG detection in cattle, sheep and goats were used. Since there was no diagnostic assay readily available for camels, a new camel-specific in-house ELISA was developed. With two exceptions, all negative reference sera were clearly negative. Two serological reactors from camels from Australia may either be non-specific immune responses or represent cross-reactions to other orthonairoviruses circulating in Australia. An importation history for these camels from endemic regions to Australia could be excluded. Furthermore, the detection of a distinct immune response of the immunized alpaca from the 14th day post immunization onwards supports the validity of the ELISA in terms of specific reactions (Table 2).

In general, serological testing for CCHFV antibodies can be considered as a challenging issue. As there are many different factors influencing the assay, findings should be interpreted carefully. Besides cross-reactivity with other Orthonairoviruses, one of the major challenges is posed by the large genetic variability linked to the geographical distribution of the virus [27]. Currently, there is no serological assay available, which can cover this broad range of genetic diversity in terms of antigenic components used in one single test. Therefore, it has to be emphasized that our in-house assays utilized antigens from Eurasian CCHFV strains.

This study provides an updated overview of the CCHFV-IgG antibody circulation in the four major livestock species in Mauritania. Using the same assay as Sas, Mertens (12), almost an identical prevalence (69% compared to 67%) was found in cattle. The seroprevalence found in sheep (16%) deviated only slightly from older data (18.3%) of Gonzalez, LeGuenno (10). Previously, only 27 goat samples have been investigated in Mauritania within a human case report study of Nabeth, Cheikh (11), detecting three positive animals (11.1%). In this study, we detected a prevalence of 15% among 233 tested goats and thus could confirm these findings. To our knowledge, camels were never screened for CCHFV-specific antibodies in Mauritania before. Only a limited number of CCHFV seroprevalence studies in camels have been carried out so far [28], with recent findings indicating prevalences of 5.3% in Iran [29], 10.5–14.4% in Niger [30], 21.3% in Sudan [31] and 67% in the United Arab Emirates [32] respectively. Using the newly established camel-specific ELISA, this study revealed a surprisingly high proportion of positive animals (81%). More detailed surveillance data on camels are therefore needed which should take the most important risk factors (age, collection site, tick infestation and husbandry system) into account to clarify the role of camelids in the CCHFV transmission and maintenance cycles.

Age and species dependent CCHFV antibody prevalences were observed for cattle and camels, as well as for sheep and goats (Fig 2 and Table 3). Significantly higher CCHFV antibody prevalences were found in young age groups (0–2 years) of cattle and camels (37% /25%) compared to sheep and goats (8% /8%). Moreover, antibody prevalences rised in the older age groups (3–4 years and older) in all species. However, cattle and camels reached more than 80% CCHFV antibody prevalences while sheep and goats of the corresponding ages remained at about 20% respectively. Interestingly, the average age of tested cattle in Hodh el Chargui (7.24 years), which had a high prevalence of 95%, was also considerably higher than the overall average age of all examined bovines (5.84 years; Tables 1 and 3). Our findings correlate well with previous observations of age-depended seroprevalences in sheep [14] and cattle [13,15,16]. Furthermore, it could be shown that the age also has a significant influence on CCHFV seroprevalences in goats and camels (Table 3 and Fig 2A).

It is clear that the steady rise of antibody prevalences with increasing age in all species can be due to an additive effect. However, hardly any experimental data are available on the CCHFV antibody persistence in livestock and wildlife, determining the extent of this effect. Obviously, higher age coincides with a greater chance of exposure to CCHFV-positive ticks in endemic regions and thus becoming infected with the virus.

CCHFV infection studies in cattle, sheep and equids revealed that all examined species develop a short-term viremia [3]. Animal infection trials in sheep demonstrated IgG antibody titers that persisted up to 30 respectively 40 days post- infection [33,34]. On the other hand, antibody persistence of up to 256 days post infection (African hedgehog) and 512 days post infection (Cape ground squirrel) was observed in wild mammals [35]. In humans, IgG antibodies were detected up to 5 years after recovery from a CCHFV infection [36]. Unfortunately, there are no experimental data for camelids to date. Therefore, more long-term CCHFV infection studies of livestock animals are necessary to improve our understanding of the humoral and cellular immunological memory in host species.

Sheep and goats represent an important source of meat in Mauritania and are therefore slaughtered at an early age, while cattle and camels are often used as dual-purpose breeds. These species are both kept for dairy farming and sent to the slaughterhouse only when milk yields decrease. For meat production, primarily young animals are slaughtered. Due to the fact that female camels produce the largest amount of milk between the 6th and 8th parity (i.e. 10–12 years of age) [37], they reach a high average age and are often slaughtered late at the age of 18–20 years when milk yields start to decrease gradually. This might explain why most of the camels in this study were older than 10 years. However, age effects alone cannot explain prevalence differences between large and small ruminants in young, as well as in old age groups. Therefore, differences in husbandry systems may also play a role in terms of CCHFV seroprevalence. It was shown for cattle [13] and small ruminants [38] that nomadic grazing will significantly increase seroprevalences due to higher tick exposition risks compared to stationary trough feeding systems. Vegetation, lack of tick treatment and the absence of poultry (which pick ticks) are also considered as potential risk factors [38]. In general, the husbandry of camels in Mauritania differs from the small ruminants. Camels are extensively kept and spend almost their entire live grazing in the bushlands. In contrast, sheep and goats are bred semi-extensively and spend less time on the pasture. They also receive more frequently veterinary treatment (antiparasitics etc.) than camels. Although there is no detailed information on the treatment of the sampled animals available, these parameters may also account for higher CCHFV prevalences in cattle and camels compared to sheep and goats of same age groups as well as for the deviating serological findings among the different regions.

Supporting information

S1 Table. ELISA results of the camel samples from Australia and German zoos used as negative reference samples.

The two Australian samples marked in yellow (Aus 26/31) are the two outliers showing a strongly deviating OD value.

(DOCX)

Acknowledgments

We thank Martina Abs, René Schöttner, Bärbel Hammerschmidt and all animal caretakers for their excellent technical support. We also thank all zoological gardens that have kindly provided serum samples from camels.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was funded by the German Office for Foreign Affairs (German Partnership Program for Biosecurity, OR12-370-43 BIOS Subsahara), the Deutsche Forschungs Gemeinschaft (DFG) (GR980/4-1 AOBJ 630130), as well as the European Union (LEAP-AGRILEARN O1DG 18024). All funding sources were raised by M. H. G. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral research. 2013;100(1):159–89. 10.1016/j.antiviral.2013.07.006 [DOI] [PubMed] [Google Scholar]
  • 2.Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. Journal of medical entomology. 1979;15(4):307–417. 10.1093/jmedent/15.4.307 [DOI] [PubMed] [Google Scholar]
  • 3.Spengler JR, Estrada-Pena A, Garrison AR, Schmaljohn C, Spiropoulou CF, Bergeron E, et al. A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus. Antiviral research. 2016;135:31–47. 10.1016/j.antiviral.2016.09.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral research. 2004;64(3):145–60. 10.1016/j.antiviral.2004.08.001 [DOI] [PubMed] [Google Scholar]
  • 5.Leblebicioglu H, Ozaras R, Irmak H, Sencan I. Crimean-Congo hemorrhagic fever in Turkey: Current status and future challenges. Antiviral research. 2016;126:21–34. 10.1016/j.antiviral.2015.12.003 [DOI] [PubMed] [Google Scholar]
  • 6.Yen YC, Kong LX, Lee L, Zhang YQ, Li F, Cai BJ, et al. Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China. Am J Trop Med Hyg. 1985;34(6):1179–82. [PubMed] [Google Scholar]
  • 7.Mint Mohamed Lemine A, Ould Lemrabott MA, Hasni Ebou M, Mint Lekweiry K, Ould Ahmedou Salem MS, Ould Brahim K, et al. Mosquitoes (Diptera: Culicidae) in Mauritania: a review of their biodiversity, distribution and medical importance. Parasites & vectors. 2017;10(1):35. 10.1186/s13071-017-1978-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Saluzzo JF, Aubry P, McCormick J, Digoutte JP. Haemorrhagic fever caused by Crimean Congo haemorrhagic fever virus in Mauritania. Trans R Soc Trop Med Hyg. 1985;79(2):268. 10.1016/0035-9203(85)90356-6 [DOI] [PubMed] [Google Scholar]
  • 9.Saluzzo JF, Digoutte JP, Camicas JL, Chauvancy G. Crimean-Congo haemorrhagic fever and Rift Valley fever in south-eastern Mauritania. Lancet. 1985;1(8420):116. 10.1016/s0140-6736(85)92014-8 [DOI] [PubMed] [Google Scholar]
  • 10.Gonzalez JP, LeGuenno B, Guillaud M, Wilson ML. A fatal case of Crimean-Congo haemorrhagic fever in Mauritania: virological and serological evidence suggesting epidemic transmission. Trans R Soc Trop Med Hyg. 1990;84(4):573–6. 10.1016/0035-9203(90)90045-g [DOI] [PubMed] [Google Scholar]
  • 11.Nabeth P, Cheikh DO, Lo B, Faye O, Vall IO, Niang M, et al. Crimean-Congo hemorrhagic fever, Mauritania. Emerg Infect Dis. 2004;10(12):2143–9. 10.3201/eid1012.040535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sas MA, Mertens M, Isselmou E, Reimer N, El Mamy BO, Doumbia B, et al. Crimean-Congo Hemorrhagic Fever Virus-Specific Antibody Detection in Cattle in Mauritania. Vector borne and zoonotic diseases. 2017;17(8):582–7. 10.1089/vbz.2016.2084 [DOI] [PubMed] [Google Scholar]
  • 13.Ibrahim AM, Adam IA, Osman BT, Aradaib IE. Epidemiological survey of Crimean Congo hemorrhagic fever virus in cattle in East Darfur State, Sudan. Ticks and tick-borne diseases. 2015;6(4):439–44. 10.1016/j.ttbdis.2015.03.002 [DOI] [PubMed] [Google Scholar]
  • 14.Wilson ML, LeGuenno B, Guillaud M, Desoutter D, Gonzalez JP, Camicas JL. Distribution of Crimean-Congo hemorrhagic fever viral antibody in Senegal: environmental and vectorial correlates. Am J Trop Med Hyg. 1990;43(5):557–66. 10.4269/ajtmh.1990.43.557 [DOI] [PubMed] [Google Scholar]
  • 15.Lotfollahzadeh S, Nikbakht Boroujeni GR, Mokhber Dezfouli MR, Bokaei S. A serosurvey of Crimean-Congo haemorrhagic fever virus in dairy cattle in Iran. Zoonoses Public Health. 2011;58(1):54–9. 10.1111/j.1863-2378.2009.01269.x [DOI] [PubMed] [Google Scholar]
  • 16.Mohamed M, Said AR, Murad A, Graham R. A serological survey of Crimean-Congo haemorrhagic fever in animals in the Sharkia Governorate of Egypt. Vet Ital. 2008;44(3):513–7. [PubMed] [Google Scholar]
  • 17.Apolloni A, Nicolas G, Coste C, El Mamy AB, Yahya B, El Arbi AS, et al. Towards the description of livestock mobility in Sahelian Africa: Some results from a survey in Mauritania. PloS one. 2018;13(1):e0191565. 10.1371/journal.pone.0191565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nicolas G, Apolloni A, Coste C, Wint GRW, Lancelot R, Gilbert M. Predictive gravity models of livestock mobility in Mauritania: The effects of supply, demand and cultural factors. PloS one. 2018;13(7):e0199547. 10.1371/journal.pone.0199547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lardeux F, Torrico G, Aliaga C. Calculation of the ELISA’s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls. Mem Inst Oswaldo Cruz. 2016;111(8):501–4. 10.1590/0074-02760160119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135–60. 10.1177/096228029900800204 [DOI] [PubMed] [Google Scholar]
  • 21.Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015;25(2):141–51. 10.11613/BM.2015.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mertens M, Wolfel R, Ullrich K, Yoshimatsu K, Blumhardt J, Romer I, et al. Seroepidemiological study in a Puumala virus outbreak area in South-East Germany. Med Microbiol Immunol. 2009;198(2):83–91. 10.1007/s00430-009-0106-9 [DOI] [PubMed] [Google Scholar]
  • 23.Mertens M, Vatansever Z, Mrenoshki S, Krstevski K, Stefanovska J, Djadjovski I, et al. Circulation of Crimean-Congo Hemorrhagic Fever Virus in the former Yugoslav Republic of Macedonia revealed by screening of cattle sera using a novel enzyme-linked immunosorbent assay. PLoS neglected tropical diseases. 2015;9(3):e0003519. 10.1371/journal.pntd.0003519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schuster I, Mertens M, Mrenoshki S, Staubach C, Mertens C, Bruning F, et al. Sheep and goats as indicator animals for the circulation of CCHFV in the environment. Experimental & applied acarology. 2016;68(3):337–46. 10.1007/s10493-015-9996-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019. [Google Scholar]
  • 26.Lenth RV. Least-Squares Means: The R Package lsmeans. J Stat Softw. 2016;69(1):1–33. [Google Scholar]
  • 27.Vanhomwegen J, Alves MJ, Zupanc TA, Bino S, Chinikar S, Karlberg H, et al. Diagnostic assays for Crimean-Congo hemorrhagic fever. Emerg Infect Dis. 2012;18(12):1958–65. 10.3201/eid1812.120710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Spengler JR, Bergeron E, Rollin PE. Seroepidemiological Studies of Crimean-Congo Hemorrhagic Fever Virus in Domestic and Wild Animals. PLoS neglected tropical diseases. 2016;10(1):e0004210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Champour M, Mohammadi G, Chinikar S, Razmi G, Shah-Hosseini N, Khakifirouz S, et al. Seroepidemiology of Crimean-Congo hemorrhagic fever virus in one-humped camels (Camelus dromedarius) population in northeast of Iran. J Vector Borne Dis. 2014;51(1):62–5. [PubMed] [Google Scholar]
  • 30.Mariner JC, Morrill J, Ksiazek TG. Antibodies to hemorrhagic fever viruses in domestic livestock in Niger: Rift Valley fever and Crimean-Congo hemorrhagic fever. Am J Trop Med Hyg. 1995;53(3):217–21. 10.4269/ajtmh.1995.53.217 [DOI] [PubMed] [Google Scholar]
  • 31.Suliman HM, Adam IA, Saeed SI, Abdelaziz SA, Haroun EM, Aradaib IE. Crimean Congo hemorrhagic fever among the one-humped camel (Camelus dromedaries) in Central Sudan. Virol J. 2017;14(1):147. 10.1186/s12985-017-0816-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Camp JV, Ahmed D, Osman BM, Shah MS, Howarth B, Khafaga T, et al. Crimean-Congo Hemorrhagic Fever Virus Endemicity in United Arab Emirates, 2019. Emerg Infect Dis. 2020;26(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gonzalez JP, Camicas JL, Cornet JP, Wilson ML. Biological and clinical responses of west African sheep to Crimean-Congo haemorrhagic fever virus experimental infection. Res Virol. 1998;149(6):445–55. 10.1016/s0923-2516(99)80013-2 [DOI] [PubMed] [Google Scholar]
  • 34.Wilson ML, Gonzalez JP, Cornet JP, Camicas JL. Transmission of Crimean-Congo haemorrhagic fever virus from experimentally infected sheep to Hyalomma truncatum ticks. Res Virol. 1991;142(5):395–404. 10.1016/0923-2516(91)90007-p [DOI] [PubMed] [Google Scholar]
  • 35.Shepherd AJ, Leman PA, Swanepoel R. Viremia and antibody response of small African and laboratory animals to Crimean-Congo hemorrhagic fever virus infection. Am J Trop Med Hyg. 1989;40(5):541–7. 10.4269/ajtmh.1989.40.541 [DOI] [PubMed] [Google Scholar]
  • 36.Yadav PD, Pardeshi PG, Patil DY, Shete AM, Mourya DT. Persistence of IgG antibodies in survivors of Crimean Congo hemorrhagic fever virus infection, India. J Infect Public Health. 2019;12(4):598–9. 10.1016/j.jiph.2019.04.005 [DOI] [PubMed] [Google Scholar]
  • 37.Musaad A, Faye B, Nikhela AA. Lactation curves of dairy camels in an intensive system. Trop Anim Health Prod. 2013;45(4):1039–46. 10.1007/s11250-012-0331-x [DOI] [PubMed] [Google Scholar]
  • 38.Kasi KK, von Arnim F, Schulz A, Rehman A, Chudhary A, Oneeb M, et al. Crimean-Congo haemorrhagic fever virus in ticks collected from livestock in Balochistan, Pakistan. Transbound Emerg Dis. 2020. [DOI] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009228.r001

Decision Letter 0

Andrea Marzi

9 Dec 2020

Dear Dr. Groschup,

Thank you very much for submitting your manuscript "Crimean-Congo hemorrhagic fever virus antibody prevalence in Mauritanian livestock (cattle, goats, sheep and camels) is stratified by the animal’s age" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Andrea Marzi

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Camel ELISA is well validated. Positive samples were confirmed in repeat measurements. Samples collected from across the country.

Reviewer #2: Please provide more detailed information regarding the sampling framework in your Methods section:

What considerations were made in determining the sample sizes? In each geographic region, how were individual animals chosen for sampling? Were they all sampled from a single herd/farm? Why were some animals only sampled from certain regions and not others?

Why was CCHFV strain Hoti utilized as the antigenic component of the Camel ELISA? Why not an African strain like IbAr10200 or UG3010? It would be nice to see a comment on this because some data suggest that even NP-based ELISA's for CCHF may lose sensitivity based on antigenic (geographic) variation (PMID: 23171700).

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Results are clearly presented.

Authors could consider presenting their seroprevalence data on the map of figure 1 to give a better spatial understanding of the data.

Reviewer #2: Please provide more detailed information/legend for Figure 1 (see Methods section comments).

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: Conclusions are well supported, authors discuss data in context of other data thoroughly and provide discussion on potential explanations for their findings.

Reviewer #2: The Discussion section references previous studies that have shown nomadic grazing can significantly impact CCHF seroprevalences (Lines 312-313). Can you comment on how this relates to your dataset (or not)? Please describe the type of livestock farming practices that are used in Mauritania (nomadic pastoralism? stationary, irrigated agricultural practices? mix of both?). Do these practices vary by the regions you sampled?

Lines 314-316: You mention vegetation or lack of tick treatments as possible parameters that could account for higher CCHFV prevalence in cattle/camels vs sheep/goats. Do you have any additional information to help lend support to these hypotheses? Is it possible comment on differences in vegetation/agroecological zones (AEZs) between sample sites or regions? What about differences in acaricide practices?

Some of the regional differences in CCHFV seroprevalence are interesting, for example, cattle in Hodh El Chargui. It would be useful to point this out & have a short discussion about why this might be.

--------------------

Editorial and Data Presentation Modifications?

Reviewer #2: Lines 70-71: Please expand on this & briefly describe the type of livestock farming practices that are used in Mauritania. Nomadic pastoralism? More stationary, irrigated agricultural practices? or a mix of both?

Line 74 mentions a "first" CCHFV serological study on cattle in Muaritania in 1983. Then, Lines 77-78 mention that cattle were tested for IgG antibodies for the first time in 2013. This is a bit confusing. What were they measuring in the 1983 study? Just a quick specification in the text would help.

Reviewer #3: Data from negative control sera from Australia and German are not presented. These data should be include in supplement or included in the main figures or tables. Also, how many samples were considered "inconclusive" and please include the results from IFA data as well.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The manuscript by Schulz et al is well written and data is clearly presented. Author's data adds to the body of knowledge on the wide prevalence of CCHFV throughout Africa but add insight onto how animal age impacts seroprevalence. Authors provide key validation data on their in-house ELISA and their conclusions are well supported. Authors discuss their results in the context of previous findings thoroughly.

Minor Comments:

Authors found that camels even at a young age were significantly more likely to be sero-positive than goats or sheep. Authors discuss that this could be due to husbandry practices. Is it known if the local population indeed have different husbandry practices for these livestock species? In regions with multiple species, is it typical for a farmer or family to have multiple species?

Some editing for grammar and syntax is needed. Ex. Lines 294-295, 290-292

Under what context were the samples outside of the capital region collected? Markets, farms, slaughterhouses?

How does the climate of the country differ across the regions?

Reviewer #3: This manuscript describe the development of an ELISA capable of detecting CCHFV antibody in camel. Rigorous validation was performed to ensure the robustness of the assay. A serosurvey was performed in sheep, cattle, camels and goats in several regions of Mauritania. The data analysis revealed that CCHFV seropositivity is strongly linked to age rather than species. I only have minor edits that can be addressed in a revised manuscript.

1) Abstract :"The reservoir and vector are ticks of the genus Hyalomma. Livestock animals (such as cattle, small ruminants and camels) develop a viremias..", replace "reservoir" by "main reservoir".

2) "he upper cut-off value ( = 1, = 2) was set to 19.96 % and samples above this value were considered to be CCHFV positive. The lower cut-off value ( = 1, = 2) was 10.45 % and samples below this value were considered as negative"

There seem to be a mistake in f value here?

--------------------

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009228.r003

Decision Letter 1

Andrea Marzi

9 Feb 2021

Dear Dr. Groschup,

We are pleased to inform you that your manuscript 'Crimean-Congo hemorrhagic fever virus antibody prevalence in Mauritanian livestock (cattle, goats, sheep and camels) is stratified by the animal’s age' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Andrea Marzi

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009228.r004

Acceptance letter

Andrea Marzi

7 Apr 2021

Dear Dr. Groschup,

We are delighted to inform you that your manuscript, "Crimean-Congo hemorrhagic fever virus antibody prevalence in Mauritanian livestock (cattle, goats, sheep and camels) is stratified by the animal’s age," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. ELISA results of the camel samples from Australia and German zoos used as negative reference samples.

    The two Australian samples marked in yellow (Aus 26/31) are the two outliers showing a strongly deviating OD value.

    (DOCX)

    Attachment

    Submitted filename: CCHFV Serology_Schulz_Rebuttal letter2.doc

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES